Everna has discovered a class of drugs that stands to have a significant disease-modifying effect on several major diseases of ageing. Today, 52% of deaths are due to diseases caused by age-related damage. Everna has drug candidates with a history of “safe use in man” that, correctly formulated, can offset the effects of ageing damage on key cell functions. The product has been found efficacious in 3 of the biggest unmet medical needs; (1) Neurodegenerative disease, (2) Atherosclerosis, and (3) Non-Alcoholic fatty liver disease.
The team comes from a diverse background of Venture Capital, Systems Biology at Cambridge, Amicus Therapeutics, Kings College, and backed by Peter Thiel, The Longevity Fund, Metro Bank, Headstart, and Capitoria.